<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> "silent" <z:hpo ids='HP_0001250'>seizures</z:hpo> after brain injury are associated with a worsening of patient outcome and are often refractory to anti-<z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epileptic</z:e> drug (AED) therapy </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study we evaluated topiramate (TPM, 1-30 mg/kg, i.v.) in a <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent model</z:e> of spontaneous non-<z:mp ids='MP_0000947'>convulsive</z:mp> <z:hpo ids='HP_0001250'>seizure</z:hpo> (<z:chebi fb="7" ids="53203">NCS</z:chebi>) activity induced by focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>For <z:hpo ids='HP_0001250'>seizure</z:hpo> detection, electroencephalographic (EEG) activity was continuously recorded for 24h in male Sprague-Dawley rats subjected to permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo) </plain></SENT>
<SENT sid="3" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume, neurological deficit, and <z:chebi fb="7" ids="53203">NCS</z:chebi> were evaluated by an experimenter blinded to the treatment group </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> vehicle treated rats (7/7) exhibited <z:chebi fb="7" ids="53203">NCS</z:chebi> following MCAo </plain></SENT>
<SENT sid="5" pm="."><plain>TPM treatment, delivered at 20 min post-occlusion and prior to <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:chebi fb="7" ids="53203">NCS</z:chebi> activity, dose-dependently reduced the incidence of <z:chebi fb="0" ids="18022">NCS </z:chebi>(ED(50)=21.1mg/kg) </plain></SENT>
<SENT sid="6" pm="."><plain>The highest dose of TPM tested (30 mg/kg) exhibited maximal reductions of 76% in the number of <z:chebi fb="7" ids="53203">NCS</z:chebi>/rat (vehicle=22.1+/-5.3, TPM=4.4+/-3.2, P&lt;0.05), 80% in the total time of <z:chebi fb="0" ids="18022">NCS </z:chebi>(vehicle=1259+/-337 s, TPM=253+/-220 s, P&lt;0.05), 20% in core <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> (vehicle=45+/-1%, TPM=36+/-4%, percent of ipsilateral volume corrected for swelling, P&lt;0.05), and 38% in neurological deficit score (vehicle=7.4+/-1.2, TPM=4.6+/-1.5, P&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Despite efficacy as a pre-<z:hpo ids='HP_0001250'>seizure</z:hpo> treatment, TPM was not effective when delivered immediately following <z:hpo ids='HP_0003674'>onset</z:hpo> of the first <z:chebi fb="7" ids="53203">NCS</z:chebi> event (36+/-5 min post-MCAo) </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, TPM exhibited significant efficacy for the prophylactic treatment of brain-injury induced <z:chebi fb="7" ids="53203">NCS</z:chebi> and represents a novel class of AED for treatment of this type of silent brain <z:hpo ids='HP_0001250'>seizure</z:hpo> </plain></SENT>
</text></document>